The neuroendocrine system and rheumatoid arthritis: Insights from anti-tumor necrosis factor-α therapy

Journal of Rheumatology

Volumn 34, Issue 7, 2007, Pages 1443-1445

  Sternberg, Esther M ^a,b   Silverman, Marni N ^c,d   Cizza, Giovanni ^e  

^a Section on Neuroendocrine Immunology and Behavior   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c Prince of Wales National Center for Complementary and Alternative Midicine   (United Kingdom)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CORTICOTROPIN RELEASING FACTOR; ETANERCEPT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; PRASTERONE; PRASTERONE SULFATE; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

CHOLINERGIC SYSTEM; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EDITORIAL; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; INFLAMMATION; NEGATIVE FEEDBACK; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS;

ADRENAL CORTEX; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DEHYDROEPIANDROSTERONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447532193     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. Ernestam S, Hafstrom I, Werner S, Carlstrom K, Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: Evidence for improved adrenal function. J Rheumatol 2007;34:1451-8
2. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153-60.
3. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006;6:318-28.
4. Crofford LJ. The hypothalamic-pituitary-adrenal axis in the pathogenesis of rheumatic diseases. Endocrinol Metab Clin North Am 2002;31:1-13.
5. Silverman MN, Pearce BD, Biron CA, et al. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol 2005;18:41-78.
6. Cutolo M, Sulli A, Pizzorni C, et al. Hypothalamic-pituitary- adrenocortical and gonadal functions in rheumatoid arthritis. Ann NY Acad Sci 2003;992:107-17.
7. Jessop DS, Harbuz MS. A defect in cortisol production in rheumatoid arthritis: why are we still looking? Rheumatology Oxford 2005;44:1097-100.
8. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003;160:1554-65.
9. Nance DM, Sanders VM. Autonomic innervation and regulation of the immune system (1987-2007). Brain Behav Immun 2007; April 26 E-pub ahead of print.
10. Straub RH, Harle P. Sympathetic neurotransmitters in joint inflammation. Rheum Dis Clin North Am 2005;31:43-59, viii.
11. Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav Immun 2005;19:493-9.
12. Silverman MN, Miller AH, Biron CA, et al. Characterization of an interleukin-6- and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection. Endocrinology 2004;145:3580-9.
13. Straub RH, Harle P, Sarzi-Puttini P, et al. Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. Arthritis Rheum 2006;54:2039-46.
14. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, et al. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998;19:101-43.
15. Ait-Ali D, Turquier V, Grumolato L, et al. The proinflammatory cytokines tumor necrosis factor-alpha and interleukin-1 stimulate neuropeptide gene transcription and secretion in adrenochromaffin cells via activation of extracellularly regulated kinase 1/2 and p38 protein kinases, and activator protein-1 transcription factors. Mol Endocrinol 2004;18:1721-39.
16. Ehrhart-Bornstein M, Bornstein SR, Scherbaum WA. Sympathoadrenal system and immune system in the regulation of adrenocortical function. Eur J Endocrinol 1996;135:19-26.
17. Cizza G, Dorn LD, Lotsikas A, et al. Circulating plasma leptin and IGF-1 levels in girls with premature adrenarche: potential implications of a preliminary study. Horm Metab Res 2001; 33:138-43.
18. Eskandari F, Cizza G. Cortisol, DHEA, the Holy Grail and the fountain of youth. J Endocrinol Invest 2002;25:753.
19. Charalampopoulos I, Alexaki VI, Tsatsanis C, et al. Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging. Ann NY Acad Sci 2006;1088:139-52.
20. Arlt W, Callies F, Allolio B. DHEA replacement in women with adrenal insufficiency - pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. Endocr Res 2000;26:505-11.